Department of Pharmacology, University of Texas Health Science Center, 7703 Floyd Curl Dr., Mail Code 7764, San Antonio, TX 78229, USA.
J Pharmacol Exp Ther. 2012 Mar;340(3):742-9. doi: 10.1124/jpet.111.188250. Epub 2011 Dec 15.
Adverse effects of benzodiazepines limit their clinical use; these effects might be reduced without altering therapeutic effects by administering other positive GABA(A) modulators (i.e., neuroactive steroids) with benzodiazepines. One concern with this strategy involves reversing these combined effects in case of overdose. The current study examined whether flumazenil can attenuate the combined effects of two benzodiazepines, midazolam and flunitrazepam, and the combined effects of midazolam and the neuroactive steroid pregnanolone, in four monkeys discriminating midazolam. Each positive modulator produced ≥80% midazolam-lever responding. Interactions between midazolam and either flunitrazepam or pregnanolone were additive. Flumazenil antagonized the benzodiazepines when they were administered alone or in combination. Schild analyses yielded slopes that did not deviate from unity, regardless of whether benzodiazepines were administered alone or together; the pA(2) value for flumazenil was 7.58. In contrast, flumazenil enhanced the effects of pregnanolone with 0.32 mg/kg flumazenil shifting the pregnanolone dose-effect curve 2-fold leftward. Flumazenil attenuated the combined effects of midazolam and pregnanolone, although antagonism was not dose-dependent. Thus, the interaction between two benzodiazepines was similar to that of a benzodiazepine and a neuroactive steroid; however, flumazenil more efficiently attenuated a combination of two benzodiazepines compared with a combination of a benzodiazepine and a neuroactive steroid. Although the magnitude of antagonism of a benzodiazepine combined with a neuroactive steroid was reduced, these results support continued exploration of the use of combinations of positive modulators to enhance therapeutic effects while reducing adverse effects.
苯二氮䓬类药物的不良反应限制了其临床应用;通过与苯二氮䓬类药物联合使用其他阳性 GABA(A)调节剂(即神经活性甾体),可以在不改变治疗效果的情况下减少这些不良反应。这种策略的一个问题是,在发生药物过量的情况下,如何逆转这些联合作用。本研究在 4 只能够区分咪达唑仑的猴子中,检验了氟马西尼是否可以减弱两种苯二氮䓬类药物(咪达唑仑和氟硝西泮)以及咪达唑仑与神经活性甾体孕烷醇酮的联合作用。每个阳性调节剂都产生了≥80%的咪达唑仑杠杆反应。咪达唑仑与氟硝西泮或孕烷醇酮的相互作用都是相加的。氟马西尼拮抗了单独或联合使用的苯二氮䓬类药物。无论苯二氮䓬类药物是单独使用还是联合使用,Schild 分析得到的斜率都没有偏离单位;氟马西尼的 pA2 值为 7.58。相比之下,氟马西尼增强了孕烷醇酮的作用,用 0.32mg/kg 的氟马西尼使孕烷醇酮的剂量-效应曲线向左移动了 2 倍。氟马西尼减弱了咪达唑仑和孕烷醇酮的联合作用,尽管拮抗作用不是剂量依赖性的。因此,两种苯二氮䓬类药物的相互作用与苯二氮䓬类药物和神经活性甾体的相互作用相似;然而,与苯二氮䓬类药物和神经活性甾体的联合作用相比,氟马西尼更有效地减弱了两种苯二氮䓬类药物的联合作用。尽管苯二氮䓬类药物与神经活性甾体联合作用的拮抗作用幅度降低,但这些结果支持继续探索使用阳性调节剂联合来增强治疗效果,同时减少不良反应。